ARS Pharmaceuticals Inc
SPRY
Company Profile
Business description
ARS Pharmaceuticals Inc is a biopharmaceutical company focused on the development of novel, potentially first-in-class product candidate, neffy for the emergency treatment of Type I allergic reactions, including anaphylaxis. neffy is a proprietary composition of epinephrine with an absorption enhancer called Intravail, which allows neffy to provide injection-like absorption of epinephrine at a low dose, in a small, easy-to-carry, easy-to-use, rapidly administered and reliable nasal spray.
Contact
11682 El Camino Real
Suite 120
San DiegoCA92130
USAT: +1 858 771-9307
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
167
Stocks News & Analysis
stocks
Chart of the Week: Aussie dividend yields are less attractive than alternatives
The latest insights from our equity research team.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,874.20 | 25.80 | 0.29% |
| CAC 40 | 8,086.05 | 20.11 | -0.25% |
| DAX 40 | 23,960.59 | 116.28 | -0.48% |
| Dow JONES (US) | 47,885.97 | 228.29 | -0.47% |
| FTSE 100 | 9,774.32 | 89.53 | 0.92% |
| HKSE | 25,468.78 | 233.37 | 0.92% |
| NASDAQ | 22,693.32 | 418.14 | -1.81% |
| Nikkei 225 | 49,512.28 | 128.99 | 0.26% |
| NZX 50 Index | 13,281.00 | 14.91 | -0.11% |
| S&P 500 | 6,721.43 | 78.83 | -1.16% |
| S&P/ASX 200 | 8,585.20 | 21.60 | 0.25% |
| SSE Composite Index | 3,870.28 | 45.47 | 1.19% |